维普中文期刊产品整合服务
159篇 您的检索式:作者名="Komajda"
    题名 作者 年代 出处 被引量
1新发贫血对慢性心力衰竭发病率和死亡率的影响:来自COMET研究的结果显示文摘Aims: Anaemia is a common comorbidity in chronic heart failure(CHF). The predictors of new onset anaemia(NOA) and its long-term prognostic value, particularly in patients treated with beta-blockers, are not known. Methods and results: In COMET, 3029 patients with CHF in NYHA Ⅱ-IV and EF< 35%were randomized to carvedilol or metoprolol tartrate and were followed for an average of 58 months. Plasma haemoglobin(Hb) concentrations were measured at a central laboratory at randomization, at four monthly intervals for the first year and annually thereafter. According to WHO criteria, anaemia was defined when Hb measured< 13 g/dL for men and< 12 g/dL for women. We considered anaemia to be severe when Hb< 11.5 g/dL for men and< 10.5 g/dL for women. The baseline mean Hb was 14.2±1.5 g/dL(n=2996) and 15.9%of patients had anaemia(males, 16.0%; females, 15.2%). At baseline, severe anaemia was found in 3.3%of patients(males, 3.6%; females, 2.0%). During the study, all-cause mortality(RR 1.47) death or hospitalization(RR 1.28), and heart failure hospitalization(RR 1.43, all P< 0.0001) were higher in anaemic when compared with non-anaemic patients. In patients without anaemia at baseline, at the end of the study, the cumulative frequency of NOA was 28.1%in males and 27.0%in females. NOA increased over time from 14.2%at year 1 to 27.5%at year 5. Predictors of NOA were: higher age, diuretic dose, creatinine(all P< 0.0001), higher serum potassium, lower serum sodium, body mass index, and use of aldosterone antagonists, carvedilol, and digitalis(all P< 0.03). Treatment with carvedilol(vs. metoprolol tartrate) was associated with a 24%increased risk to develop NOA(P=0.0047),but not severe anaemia(P=0.18). Patients with a Hb decrease of >3 g/dL(RR 3.37, P< 0.0001) or of 2.0-3.0 g/dL(RR 1.47, P=0.011) from baseline had an increased subsequent mortality when compared with patients having Hb increases of 0-1.0 g/dL. Conclusion: In stable ambulatory CHF patients, development of NOA is frequent and can be predicted by a set of clinical variables. Decreases in Hb over time relate to future increased morbidity and mortality.Komajda M. Anker S.D. Charlesworth A. 郭俊 2006世界核心医学期刊文摘(心脏病学分册)2006,,12:14
2Predictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey显示文摘Periaswamy Velavan Nasrin K. Khan Kevin Goode Alan S. Rigby Poay H. Loh Michel Komajda Ferenc Follath Karl Swedberg Hugo Madeira John G.F. Cleland 2008International Journal of Cardiology2008,,1:2
3Heart rate as a risk factor in chronic heart failure (SHIFT):the association between heart rate and outcomes in arandomised placebo-controlled trial显示文摘Bohm M Swedberg K Komajda M 2010Lancet2010,376,9744:1
4Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo- controlled trial显示文摘Bohm M Swedberg K Komajda M 2010Lancet2010,376,9744:1
5Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echoeardiography substudy显示文摘Tardif JC Meara EO Komajda M 2011Eur Heart J2011,32,20:1
6Factors predicting mortality in idiopathic dilated cardiomyopathy显示文摘KOMAJDA M JAIS J P REEVES F 1990Eru Heart J1990,11,:1
7Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)显示文摘Komajda M Carson PE Hetzel S 2011Circ Heart Fail2011,4,1:1
8Ivabradine and outcomes in chronicheart failure (SHIFT) :a randomised placebo-controlled study 显示文摘Swedberg K Komajda M Bohm M 2010Lancet2010,376,9744:1
9Ivabradine andoutcomes in chronic heart failure (SHIFT): a randomisedplacebo-controlled study 显示文摘Swedberg K Komajda M Bohm M 2010Lancet2010,376,9744:1
10Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure:Is there an influence of beta-blocker dose?:Findings from the SHIFT(Systolic Heart failure treatment with the I f inhibitor ivabradine Trial)study显示文摘Swedberg K Komajda M Bohm M 2012Journal of the American College of Cardiology2012,59,22:1
11Clinical trials in acute heart failure : simpler solutions to complex problems显示文摘McDonagh TA Komajda M Maggioni AP 2011Eur J Heart Fail2011,13,10:1
12Heart failure with preserved ejection fraction: clinical characteristics of patients enrolled in the I-PRESERVE trial显示文摘McMurray JJ Carson PE Komajda M 2008Eur J Heart Fail2008,10,2:1
13Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure显示文摘Richard Isnard Fran?oise Pousset Jean-No?l Trochu Olga Chafirovska??a Alain Carayon Jean-Louis Golmard Philippe Lechat Daniel Thomas Jean-Brieuc Bouhour Michel Komajda 2000The American Journal of Cardiology2000,,4:1
14Molecular genetics in hypertrophic cardiomyopathy : towards individualized management of the disease 显示文摘Charron P Komajda M 2006Expert Rev Mol Diagn2006,6,1:1
15Heart rate reductionwith ivabradine and health related quality of life in patientswith chronic heart failure: results from the SHIFT study显示文摘Ekman I Chassany O Komajda M 2011Eur Heart J2011,,:1
16Ivabradine andoutcomes in chronic heart failure (SHIFT) : a randomisedplacebo-controlled study 显示文摘Swedberg K Komajda M* Bohm M 2010Lancet2010,376,9744:1
17Ivabradine and outcomes in chronic heart failure(shift):a randomised placebo-controlled study显示文摘SWEDBERG K KOMAJDA M BHM M 2010The Lancet2010,376,9744:1
18Heart failure with preserved ejection fraction:clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial显示文摘McMurray JJ Carson PE Komajda M 2008Eur J Heart Fail2008,10,2:1
19Clinical profilesand outcomes in patients with chronic heart failure andchronic obstructive pulmonary disease: an efficacy and safetyanalysis of SHIFT study 显示文摘Tavazzi L Swedberg K Komajda M 2013Int J Cardiol2013,170,2:1
20Prevalence and impact of worse- ning renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH)显示文摘Cowie M R Komajda M Murray-Thomas T Underwood J Ti- cho B POSH Investigators 2006Eur Heart J2006,27,:1
返回顶部 每页显示:
共8页 首页 上一页 第1页 下一页 末页 /8 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费